News

Clinical-stage biotech Nektar Therapeutics (NASDAQ: NKTR) had some encouraging news to report from the lab about one of its investigational medicines on Thursday. As often happens in such

Nektar Therapeutics (NASDAQ: NKTR) stock surged by more than 20% in the week to Friday morning. The move wasn't so much caused by anything specific to Nektar's drug development program. Instead

Medical device and diagnostics company Bruker (NASDAQ: BRKR) wasn't looking like the cure for any investor's ailments on Wednesday. The stock was hit with an assertive sell-off from the market

HealthEquity (NASDAQ:HQY), a leading provider of Health Savings Account (HSA) custodial services in the United States, reported fiscal 2026 second-quarter earnings on Sept. 2. The release noted

Premier (NASDAQ:PINC), a leading provider of healthcare supply chain and performance improvement solutions, reported its fiscal fourth-quarter results on August 20, 2025, for the period ended June

Premier(NASDAQ:PINC) reported fourth quarter and full-year 2025 results on August 19, 2025, with revenue of $986 million and adjusted EPS of $1.54, both exceeding guidance. The company’s Supply

Biotech Nektar Therapeutics (NASDAQ: NKTR) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for

Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biopharmaceutical company focusing on immunology and oncology drug development, reported its latest financial results on August 7, 2025, for the

Insulet (NASDAQ:PODD), a medical device company specializing in wearable insulin delivery systems, released its second quarter 2025 earnings on August 7, 2025. The headline news was strong

Orion (NYSE:OEC), a leading global producer of carbon black, reported its second quarter results on August 6, 2025. The most notable news was that GAAP revenue came in at $466.4 million for Q2 2025

Royalty Pharma Plc (NASDAQ:RPRX), a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts—its

BeOne Medicines (NASDAQ:ONC), a global oncology-focused pharmaceutical company, released results for Q2 2025 on August 6, 2025. The most notable news was a sustained acceleration across revenue

Amentum (NYSE:AMTM), a leading provider of engineering, technical, and mission support services to government and commercial customers, reported results for Q3 FY2025 on August 5, 2025. The earnings

Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered antibodies for serious diseases, reported second quarter 2025 results on August 6, 2025. The company’s GAAP

Orion Energy Systems (NASDAQ:OESX), a provider of energy-efficient LED lighting and electric vehicle (EV) charging solutions, released its results for the quarter ended June 30, 2025, on August 6

Ultragenyx Pharmaceutical (NASDAQ:RARE), a rare disease drug developer, reported its second quarter 2025 earnings on August 5, 2025. Both revenue and earnings per share exceeded Wall Street

Halozyme Therapeutics (NASDAQ:HALO), a biotechnology company specializing in drug delivery innovations, released its second-quarter 2025 results on August 5, 2025. The quarter’s headline is

Image source: The Motley Fool.

Need a quote from a Motley Fool analyst? Email [email protected]

Columbia Banking System(NASDAQ:COLB) delivered operating results for fiscal Q2 2025 reflecting a 14%